Abstract
Candida albicans, a commonly encountered fungal pathogen, causes diseases varying from superficial mucosal complaints to life-threatening systemic disorders. Among the virulence traits of C. albicans, yeast-to-hypha transition is most widely acknowledged. Host innate immunity to C. albicans critically requires pattern recognition receptors (PRRs), and defence against C. albicans infection is provided by an exquisite interplay between the innate and adaptive arms of the host immune system.
Fungal infections in the human population have risen substantially in the past several decades.Citation1 This increase is largely due to the AIDS pandemic and some advents in modern medicine, including massive chemotherapy, organs transplantation, immunosuppression, and implantable medical devices. Candida albicans is a commonly encountered fungal pathogen. It may cause diseases varying from superficial mucosal infections to systemic disorders with high mortality rate. Notably, clinical available antifungal agents are limited, and drug resistance is a significant challenge.Citation2
Yeast-to-hypha transition is a widely acknowledged virulence trait of C. albicans. The transition is controlled by multiple regulatory circuits, among which the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway plays a major role. A central component of the cAMP/PKA pathway is Cyr1 (also known as Cdc35), the sole adenylyl cyclase of C. albicans that catalyzes cAMP synthesis. To investigate how Cyr1 activity is regulated, the identification of interacting partners of Cyr1 will definitely provide some important information.Citation3
C. albicans is a commensal fungus that colonizes on genital/gastrointestinal mucosa without causing disease, and only in immunosuppressed hosts can C. albicans become pathogenic. The interaction between C. albicans and the host immune system plays an important role in both commensalism and infection. In recent years, more and more studies have focused on immune defense mechanisms against C. albicans.
Host innate immunity to C. albicans critically requires pattern recognition receptors (PRRs).Citation4 PRRs are involved in the recognition of C. albicans in epithelial cells, neutrophils, endothelial cells, monocytes/macrophages, dendritic cells (DCs), etc. The present known PRRs of C. albicans include Toll-like receptors (TLRs), C-type lectin receptors (CLRs), and Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), among which CLRs and TLRs are major. Of note, Dectin-1, one of the CLRs, recognizes β-glucans on cell wall of C. albicans, and the rest CLRs recognize different mannose-relative structures. Ligation of Dectin-1 can stimulate a variety of cellular responses, including activation of nuclear transcription factor NF-κB and IRF5, ERK-MAPK pathway, NLRP3 inflammasome, phagocytosis, respiratory burst and Rubicon. Interestingly, Dectin-1 can collaborate with TLRs to orchestrate antifungal immunity.Citation5
During C. albicans bloodstream infection, which may present as sepsis and septic shock, innate responses govern the early response. Neutrophils are considered principal effector cells conferring protection. Neutrophil activation is closely linked to complement and modulated by activated mononuclear cells. A thorough understanding of these mechanisms is helpful to treat patients suffering from systemic candidiasis.Citation6
Defense against C. albicans infection is provided by an exquisite interplay between the innate and adaptive arms of the host immune system. DCs are specialized antigen presenting cells (APCs) and serve as a critical conduit between the innate and adaptive immune responses. T-cells are an integral component of the host adaptive immune response to C. albicans, and the Th1 and Th17 cellular responses play a central role.Citation1
Based on the findings on antifungal immune response, some progress has been obtained on developing C. albicans vaccines, including live attenuated C. albicans strain, protein vaccines, and glycoconjugates vaccines. Although the currently available vaccines have been demonstrated protective, some more efforts are still needed to achieve a vaccine applicable in patients.Citation7
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Funding
YW is sponsored by the National Natural Science Foundation of China (81273558) and the Shanghai Pujiang Program (14PJD001).
References
- Richardson JP, Moyes DL. Adaptive immune responses to Candida albicans infection. Virulence 2015; PMID:25607781
- Costa C, Dias PJ, Sá-Correia I, Teixeira MC. MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? Front Physiol 2014; 5:197; PMID:24904431.
- Bai C, Xu XL, Wang HS, Wang YM, Chan FY, Wang Y. Characterization of a hyperactive Cyr1 mutant reveals new regulatory mechanisms for cellular cAMP levels in Candida albicans. Mol Microbiol 2011; 82(4):879-93; PMID:21992526.
- Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 2011; 10(2):112-22; PMID:22158429.
- Jia XM, Tang B, Zhu LL, Liu YH, Zhao XQ, Gorjestani S, Hsu YM, Yang L, Guan JH, Xu GT, Lin X. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. J Exp Med 2014; 211(11):2307-21; PMID:25267792.
- Losse J, Zipfel PF, Józsi M. Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J Immunol 2010; 184(2):912-21; PMID:20008295.
- Wang XJ, Sui X, Yan L, Wang Y, Cao YB, Jiang YY. Vaccines in the treatment of invasive candidiasis. Virulence 2015; PMID:25559739.